Microdose GLP-1 cost

Why we label prices instead of just listing themA caution about every compounded-price figure you will read anywhere, including on this page. Comparison sites in this category publish flatly contradictory numbers for the same providers — we have seen the same program listed at $179 on one site and $259 on another in the same month, and 'cheapest tirzepatide' claims ranging from $99 to $169 depending on who is writing. Advertised rates also frequently apply only to a first month, a starter dose, or a 12-month prepaid commitment.

We therefore label every provider price with its evidence status rather than presenting all figures as equally solid, and we treat any compounded price we have not captured ourselves as Reported, not Verified. Brand pricing on this page is verified directly against manufacturer sources, which is why we lead with it.

The 45-day trapThe 45-day clock runs from the delivery date of your previous shipment, not the order date. Miss it at 10 mg or above and the price jumps from $449 to $699 — a $250 penalty for being a week late. This is the single most expensive piece of fine print in the category.

The finding most comparison sites will not printThe economic case for compounded GLP-1 has narrowed sharply, and almost no comparison site says so. In 2023 the choice was roughly $1,000+/month for brand versus $150–$300 for compounded — a gap wide enough to justify real regulatory risk. As of October 15, 2026, brand Zepbound is $299–$449 through LillyDirect, the Wegovy pen is $349 and the Wegovy pill $149 at its 1.5 mg starting dose ($299 at maintenance doses) through NovoCare, and commercial coverage with a savings card can bring brand costs to about $25. Compounded programs in our index charge $99–$399 at their lowest standing price.

For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.

Pricing is time-sensitiveThese figures change frequently. The date above is the last verification; treat any pricing older than a month as provisional.

Compounding statusCompounded drugs are not FDA-approved: the agency does not review them for safety, effectiveness or quality before they are marketed. Federal law also bars compounding drugs that are essentially a copy of a commercially available approved product — a bar that is lifted only while the drug is on the FDA shortage list. Both shortages are over. The FDA declared the tirzepatide shortage resolved on October 2, 2024 and the semaglutide shortage resolved on February 21, 2025, and enforcement discretion ended for all compounders between February 18 and May 22, 2025. On April 30, 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list on a finding of no clinical need. Routine compounding of these molecules is therefore no longer lawful on the basis that made the market — a fact most comparison sites still describe as "permanent legitimacy." It is not. The comment period on the 503B proposal closed July 30, 2026, and no final decision had been published as of October 15, 2026. On September 18, 2026 FDA told Empower Pharmacy that compounded tirzepatide and semaglutide products it examined “appear to be essentially copies” of approved drugs (warning letter 738238).